Acasta Partners UK LLP Portfolio

Auto-discovered active 13F filer.

SEC 13F CIK: 0002090007

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedConsumer TiltHigh Turnover how tags are computed

Q3 2026 Q2 2026 Q1 2026 Q4 2025

Q3 2026 · 17 positions · Total reported value $191.17M · Top-10 concentration 96.1% · Updated 2026-10-09

Last updated: 2026-10-09 · Source: SEC EDGAR Form 13F-HR

Turnover: 40.0% · 3 new · 2 cut · 3 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -19.5% · vs SPY -21.6% · Prev Value $188.67M — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -12.6% · vs SPY -14.8% · Latest Value $191.17M — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q3 2026 13F filing, Acasta Partners UK LLP disclosed 17 equity positions with a combined reported value of $191.17M. The filing implies a focused portfolio: its ten largest positions account for 96.1% of reported value. HoldingsHub classifies the profile as Small / Focused / Consumer Tilt / High Turnover.

The largest disclosed positions as of Q3 2026 were BABA ($84.53M), LAR ($31.12M), MUX ($18.48M). By sector, the heaviest allocations are Consumer Discretionary 44.2%, Materials 32.7%. Versus the prior quarter, allocation shifted toward Other (+2.9pp), Health Care (+1.7pp) and away from Consumer Discretionary (-1.2pp), Energy (-1.2pp).

Versus the prior quarter, Acasta Partners UK LLP opened 3 new positions, trimmed 2 and fully exited 3, a turnover rate of 40.0% of positions. The portfolio's overlap with the prior quarter was 70% of names.

The largest new positions opened in Q3 2026 were OPI ($8.63M), VRDN ($5.74M), NFE ($182.70K).

Of the 3 positions fully exited versus the prior quarter, the largest were HIVE ($3.64M), DSXWS ($8.93K), CORZW ($19).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2026)

  • OPI OFFICE PPTYS INCOME TR · $8.63M
  • VRDN VIRIDIAN THERAPEUTICS INC · $5.74M
  • NFE NEW FORTRESS ENERGY INC · $182.70K

Fully Exited (vs previous quarter)

  • HIVE HIVE DIGITAL TECHNOLOGIES LT · prev qtr: $3.64M
  • DSXWS DIANA SHIPPING INC · prev qtr: $8.93K
  • CORZW CORE SCIENTIFIC INC NEW WT EXP TRANCHE 1 · prev qtr: $19

Insider Transactions (Form 4)

Latest Acasta Partners UK LLP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Acasta Partners UK LLP, based in London, United Kingdom, files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q3 2026) lists 17 positions worth $191.17M in total. HoldingsHub carries 4 quarters of its filings (Q4 2025–Q3 2026).

Firm Snapshot

  • Headquarters: LONDON, United Kingdom
  • SEC registration: 801-134119 (status: Approved), registered 2025-08-12
  • Regulatory AUM (Form ADV): $51.77M as of 2026-06-29
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 1 private funds, of which 1 hedge funds

Portfolio Structure

  • 17 positions · $191.17M reported value (Q3 2026)
  • Top 10 holdings = 96.1% of reported value
  • Largest position: BABA (ALIBABA GROUP HLDG LTD FSPONSORED ADR 1 ADR REPS 8 ORD SHS) at 44.2%
  • Average position size: $11.25M

Sector Tilt

  • Consumer Discretionary 44.2%
  • Materials 32.7%
  • Energy 6.6%
  • (classified holdings cover 89% of value)

Quarterly Activity

  • Q3 2026: 3 new, 2 added, 2 reduced, 3 exited
  • 10 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall Direction and Market View: Acasta Partners UK LLP appears to be maintaining a conservative stance with a slight preference for materials and health care sectors. The reduction in Alibaba Group Holding-ADR (BABA) suggests a cautious approach to the consumer discretionary sector, which may be reflecting broader market concerns or sector-specific issues. 2. Key Moves: - Reduced: Alibaba Group Holding-ADR (BABA) by 6.9% in shares, indicating a potential concern about the company or the sector. - Added: Office Properties Income Trust (OPI) and Viridian Therapeutics Inc (VRDN), suggesting a focus on income generation and potentially biotechnology or health care innovation. - Added significantly: Hudbay Minerals Inc (HBM) by 75.7% in shares, reflecting an increased interest in the materials sector. - Added moderately: Celcinity Inc (CELC) by 25.0% in shares, indicating a belief in the potential of the health care sector. 3. Portfolio Structure: - Passive/Active: The fund seems to lean towards a passive approach, as it maintains or reduces positions in many holdings without significant changes in strategy. - Sector Bias: The portfolio is biased towards materials and health care sectors, which could reflect a belief in the long-term growth potential of these sectors. - Risk Appetite: The risk appetite is moderate, with a conservative reduction in positions in some sectors and a strategic increase in others. 4. Per-Holding One-Liner: - BABA: Largest position in the consumer discretionary sector; unverified. - LAR: Lithium Argentina AG, involved in lithium mining; unverified. - MUX: McEwen Inc., a gold and silver exploration and production company; unverified. - HYG: iShares TR, a high-yield bond exchange-traded fund; unverified. - METC: Ramaco Resources, an oil and gas exploration and production company; unverified. - OPI: Office Properties Income Trust, a real estate investment trust; unverified. - VRDN: Viridian Therapeutics Inc, a biotechnology company focused on cancer immunotherapy; unverified. - HBM: Hudbay Minerals Inc, a mining company with operations in copper, zinc, and gold; unverified. - CELC: Celcinity Inc, a biotechnology company focusing on cancer immunotherapy; unverified. - CCJ: Cameco Corp, a uranium producer; unverified. 5. One-Sentence Style Summary: Acasta Partners UK LLP maintained a cautious stance in Q3 2026, reducing exposure to the consumer discretionary sector while increasing its focus on materials and health care, reflecting a balanced approach to potential market uncertainties.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice.

Sector Allocation

Materials 32.7%
Energy 6.6%
Utilities 0.1%
Other 11.3%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 67.50M $84.53M 44.22%
44.22%
Reduce
2 31.51M $31.12M 16.28%
16.28%
Hold
3 10.00M $18.48M 9.66%
9.66%
Hold
4 168.09K $12.98M 6.79%
6.79%
Reduce
5 20.00M $12.61M 6.60%
6.60%
Hold
6 541.72K $8.63M 4.51%
4.51%
New
7 5.00M $5.74M 3.00%
3.00%
New
8 197.35K $5.27M 2.76%
2.76%
Add
9 2.50M $2.41M 1.26%
1.26%
Add
10 22.11K $1.92M 1.00%
1.00%
Hold
11 1.50M $1.54M 0.81%
0.81%
Hold
12 97.90K $1.38M 0.72%
0.72%
Hold
13 142.62K $1.35M 0.70%
0.70%
Hold
14 150.70K $1.34M 0.70%
0.70%
Hold
15 131.79K $1.20M 0.63%
0.63%
Hold
16 100.00K $498.88K 0.26%
0.26%
Hold
17 29.14K $182.70K 0.10%
0.10%
New

Holdings Prediction Model

Predicts next-quarter Top-10 holdings and weights from the fund's own historical trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through quarter T. Weights are shares of the modelled portfolio.

The next-quarter predicted Top 10 (2026-Q4) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.

Latest-Quarter Accuracy (2026-Q3)

P 80% R 80% F1 80% (modelled on 2026-Q2; 8/10 hit)

Historical Backtest (2 quarters)

Avg precision 80% · recall 80% · F1 80% · avg rank error 1.8 · Top-10 turnover 23%

Quarter Prec. Recall F1 Predicted Top 10 Actual Top 10
2026-Q2 80% 80% 80% BABA · LAR · MUX · PRGS · METC · SVM · HYG · CELC · CCJ · HBM BABA · LAR · MUX · HYG · METC · CELC · HIVE · HBM · CCJ · USAR
2026-Q3 ★ 80% 80% 80% BABA · LAR · MUX · HYG · METC · CELC · HIVE · HBM · CCJ · USAR BABA · LAR · MUX · HYG · METC · OPI · VRDN · HBM · CELC · CCJ

★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.

FAQ

What did Acasta Partners UK LLP buy in 2026-Q3?

In its 2026-Q3 13F filing, Acasta Partners UK LLP reported 17 equity positions worth $191.17M in aggregate; its largest disclosed positions were BABA ($84.53M), LAR ($31.12M), MUX ($18.48M).

How large is Acasta Partners UK LLP's portfolio?

Acasta Partners UK LLP reported $191.17M of long equity holdings across 17 positions as of 2026-Q3. Top-10 holdings account for 96.1% of reported value.

What is Acasta Partners UK LLP's investment style?

HoldingsHub classifies the portfolio as Small / Focused / Consumer Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/acasta-partners-uk/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →